New hope for people suffering from pancreatic cancer
Revolutionary study results thanks to the VivaScope 2500 laser scanning microscope.
(Munich, 17.11.2022) Pancreatic cancer usually means a death sentence. In 2021, 19,400 people developed the disease, of whom 18,000 died. With a 5-year survival rate of only 5%, pancreatic cancer is therefore the fourth leading cause of cancer death in Western countries. However, with early detection, this rate can be increased to 20%, making early detection with accurate diagnosis crucial and thus having a significant impact on clinical behavior.
Munich-based VivaScope GmbH has achieved excellent results with its VivaScope 2500 laser scanning microscope in a study. This 81-patient study evaluated the diagnostic performance of VivaScope technology in predicting the histologic adequacy of EUS-FNA/FNB specimens in solid pancreatic lesions and the agreement with the final histologic evaluation.
Advantages of the new approach:
- Real-time, intraoperative, on-site or remote evaluation.
- Prompt feedback on the pathological status of the harvested tissue, allowing immediate treatment to be initiated
- Complete tissue integrity for subsequent laboratory testing
- Sample preparation does not require a specialized operator
- Significant time & cost savings
- Ability to diagnose remotely via telemedicine
The result may be seen as a revolution and gives hope to pancreatic cancer patients:
VivaScope sensitivity was 100%, specificity was 66.7%, accuracy was 97%, positive predictive value was 97%, and negative predictive value was 100%.
The VivaScope 2500 represents a new technique that can be successfully applied to cytological microhistological specimens. It provides immediate information on the suitability of the tissue and shows very good agreement with the final histology. In a subsequent study, EUS-FNA/FNB VivaScope images were evaluated by pathologists from 10 international centers to investigate the concordance between the observers with the final diagnostic report.
Attachements
Contact person:
Other press releases
News
5th Generation: Ex Vivo 2500 for Instant Digital Pathology
Munich, 26th September 2025 – VivaScope is happy to announce the launch of the new Generation 5 Ex Vivo. This innovative generation offers significant technological improvements that will improve one more time the workflow for pathologists, pulmonoligists and dermatologists. With Generation 5, we have taken the Ex Vivo VivaScope 2500 to the next level by implementing advanced technologies starting with optimised slide handling, through new imaging modes, to a completely new and larger objective.
News
Prospective Validation of Ex Vivo Fusion Confocal Microscopy for Intraoperative Margin Assessment in Breast-Conserving Cancer Surgery
Munich, July 3 2026 – In this publication, the authors report a prospective validation study aiming to consolidate the clinical applicability of VivaScope® 2500 in breast-conserving surgery.
News
Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Non-randomised Feasibility Study
Munich / Cambridge, March 10, 2026 – In this publication, the authors report the description of the initial experience with a one-stop renal mass biopsy (RMB) clinic in which the VivaScope® 2500 is used as part of a novel pathway.
News
VivaScope again main sponsor of the World Confocal Laser Microscopy Congress
Leading international confocal microscopy experts trust in VivaScope technology from Munich
News
Priv.-Doz. Dr. Daniela Hartmann wins the “German Medical Award”
Great success also for VivaScope, the specialist for confocal laser scanning microscopy, because the VivaScope 2500 was part of it.
News
Economic value of the VivaScope 1500 In Vivo microscope
Extensive large-scale clinical trial demonstrated the therapeutic & economic value of the VivaScope 1500 In Vivo microscope in early diagnosis of Melanoma lesions.